Code
lsting <- as_listing(
out,
key_cols = "USUBJID",
disp_cols = names(out),
main_title = paste0(
"Listing of Anti-", drugcd, " Antibody Data for Treatment Emergent ADA Positive Patients, PK Population",
"\nProtocol: ", unique(adab$PARCAT1)[1]
),
subtitles = paste("\nTreatment Group:", trt),
main_footer = "Minimum reportable titer = 1.10 (example only)
--- = No sample evaluated
ADA = Anti-Drug Antibodies (is also referred to as ATA, or Anti-Therapeutic Antibodies)
Number of patients positive for Treatment Emergent ADA = the number of post-baseline evaluable patients determined to have treatment-induced ADA or treatment-enhanced ADA during the study period.
Treatment-induced ADA = a patient with negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result.
Treatment-enhanced ADA = a patient with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result.
Transient ADA = ADA positive result detected (a) at only one post-baseline sampling timepoint (excluding last timepoint) OR (b) at 2 or more timepoints during treatment where the first and last ADA positive samples are separated by a period of < 16 weeks, irrespective of any negative samples in between.
Persistent ADA = ADA positive result detected (a) at the last post-baseline sampling timepoint, OR (b) at 2 or more time points during treatment where the first and last ADA positive samples are separated by a period ≥ 16 weeks, irrespective of any negative samples in between.
Asterisk denotes sample that tested positive for Neutralizing Antibodies."
)
head(lsting, 20)
Listing of Anti-R1800000 Antibody Data for Treatment Emergent ADA Positive Patients, PK Population
Protocol: A: Drug X Antibody
Treatment Group: A: Drug X
—————————————————————————————————————————————————————
Day 2 Patient Treatment
Subject ID (Day 1) Emergent ADA Status
—————————————————————————————————————————————————————
AB12345-BRA-1-id-105 --- Enhanced
AB12345-BRA-1-id-134 --- Enhanced
AB12345-BRA-1-id-42 --- Enhanced
AB12345-BRA-1-id-93 --- Enhanced
AB12345-BRA-11-id-217 --- Enhanced
AB12345-BRA-11-id-345 --- Enhanced
AB12345-BRA-11-id-397 --- Enhanced
AB12345-BRA-11-id-50 --- Enhanced
AB12345-BRA-13-id-177 --- Enhanced
AB12345-BRA-14-id-23 --- Enhanced
AB12345-BRA-15-id-36 --- Enhanced
AB12345-BRA-2-id-296 --- Enhanced
AB12345-BRA-6-id-369 --- Enhanced
AB12345-CAN-1-id-18 --- Enhanced
AB12345-CAN-11-id-139 --- Enhanced
AB12345-CAN-14-id-104 --- Enhanced
AB12345-CHN-1-id-119 --- Enhanced
AB12345-CHN-1-id-123 --- Enhanced
AB12345-CHN-1-id-133 --- Enhanced
AB12345-CHN-1-id-199 --- Enhanced
—————————————————————————————————————————————————————
Minimum reportable titer = 1.10 (example only)
--- = No sample evaluated
ADA = Anti-Drug Antibodies (is also referred to as ATA, or Anti-Therapeutic Antibodies)
Number of patients positive for Treatment Emergent ADA = the number of post-baseline evaluable patients determined to have treatment-induced ADA or treatment-enhanced ADA during the study period.
Treatment-induced ADA = a patient with negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result.
Treatment-enhanced ADA = a patient with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result.
Transient ADA = ADA positive result detected (a) at only one post-baseline sampling timepoint (excluding last timepoint) OR (b) at 2 or more timepoints during treatment where the first and last ADA positive samples are separated by a period of < 16 weeks, irrespective of any negative samples in between.
Persistent ADA = ADA positive result detected (a) at the last post-baseline sampling timepoint, OR (b) at 2 or more time points during treatment where the first and last ADA positive samples are separated by a period ≥ 16 weeks, irrespective of any negative samples in between.
Asterisk denotes sample that tested positive for Neutralizing Antibodies.